| HOME >> BIOLOGY >> TECHNOLOGY |
Cost of
products
sold 27,211,681 (154,726) (253,879)(2,012,734) 24,790,342
Research
and
development 17,200,762 (92,630) (849,678) (10,250) 16,248,204
Sales and
marketing 14,747,333 (71,474) (262,148)(2,382,915) 12,030,796
General
and
admini-
strative 12,827,771 (4,898)(1,627,173)(2,482,929) 8,712,771
Loss on
sale of
endovascular
assets 1,212,478 - - (1,212,478) -
Total
operating
costs
and
expenses 73,200,025 (323,728)(2,992,878)(8,101,306) 61,782,113
Income from
operations 6,590,872 323,728 2,992,878 8,101,306 18,008,784
Interest and
other income,
net 15,088 - - - 15,088
Pre-tax
income 6,605,960 323,728 2,992,878 8,101,306 18,023,872
Income tax
expense 1,816,179 108,606 1,004,066 2,717,867 5,646,717
Net income $4,789,781 $215,122 $1,988,812 $5,383,439 $12,377,155
Basic
earnings
per share $0.40 $0.02 $0.17 $0.45 $1.04
Diluted
earnings
per share $0.38 $0.02 $0.16 $0.43 $0.99
Weighted
average
common
shares
outstand-
ing 11,891,469 11,891,469 11,891,469 11,891,469 11,891,469
Diluted
weighted
average
common
shares
outstanding 12,471,298 12,471,298 12,471,298 12,471,298 12,471,298
| SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved |